Abbvie Inc (ABBV) concluded trading on Thursday at a closing price of $179.44, with 3.88 million shares of worth about $695.84 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.52% during that period and on Thursday the price saw a gain of about 0.98%. Currently the company’s common shares owned by public are about 1.77B shares, out of which, 1.77B shares are available for trading.
Stock saw a price change of -0.31% in past 5 days and over the past one month there was a price change of -1.28%. Year-to-date (YTD), ABBV shares are showing a performance of 0.98% which increased to 12.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $153.58 but also hit the highest price of $207.32 during that period. The average intraday trading volume for Abbvie Inc shares is 6.13 million. The stock is currently trading 2.01% above its 20-day simple moving average (SMA20), while that difference is down -0.87% for SMA50 and it goes to 0.36% higher than SMA200.
Abbvie Inc (NYSE: ABBV) currently have 1.77B outstanding shares and institutions hold larger chunk of about 72.96% of that.
The stock has a current market capitalization of $317.10B and its 3Y-monthly beta is at 0.57. PE ratio of stock for trailing 12 months is 62.58, while it has posted earnings per share of $2.87 in the same period. Its PEG reads 7.45 and has Quick Ratio of 0.54 while making debt-to-equity ratio of 11.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABBV, volatility over the week remained 1.10% while standing at 1.82% over the month.
Analysts are in expectations that Abbvie Inc (ABBV) stock would likely to be making an EPS of 2.98 in the current quarter, while forecast for next quarter EPS is 2.63 and it is 12.18 for next year. For the current quarter EPS, analysts have given the company a lowest target 2.9 which is 3.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 2.79 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -1.53% while it is estimated to increase by 11.53% in next year. EPS is likely to grow at an annualized rate of 8.40% for next 5-years, compared to annual growth of -5.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 10, 2024 offering a Neutral rating for the stock and assigned a target price of $191 to it. Coverage by Daiwa Securities stated Abbvie Inc (ABBV) stock as a Neutral in their note to investors on December 05, 2024, suggesting a price target of $180 for the stock. On November 22, 2024, Leerink Partners Upgrade their recommendations, while on November 15, 2024, Wolfe Research Initiated their ratings for the stock with a price target of $205. Stock get a Buy rating from Argus on November 04, 2024.
